Overview

Auto Injectors Market is poised to register a CAGR of 17.9% during the forecast period 2022 to 2028.  

FutureWise Market Research has instantiated a report that provides an intricate analysis of Auto Injectors Market trends that shall affect the overall market growth. Furthermore, it includes detailed information on the graph of profitability, SWOT analysis, market share and regional proliferation of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of this market.

Key market players included in the Auto Injectors Market are:
• Abbvie
• Mylan
• ELI Lilly
• Ypsomed
• Amgen
• Becton Dickinson and Co.
• Owen Mumford
• Consort Medical
• Haselmeir
• Shl Group
• Johnson & Johnson
• Teva
• Antares Pharma
• Sanofi 
• Pfizer, Inc.

Auto Injectors Market Segmentation:
By Therapy
• Rheumatoid Arthritis
• Multiple Sclerosis
• Diabetes
• Anaphylaxis
• Other Therapies
By Type
• Disposable Auto Injectors
• Reusable Auto Injectors
  o Prefilled Auto Injectors
  o Empty Auto Injectors
By End User
• Home Care Settings
• Hospitals & Clinics
• Ambulatory Care Settings
By Route of Administration
• Subcutaneous
• Intramuscular
By Region
• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East and Africa

Competitive Landscape:
• Tier 1 players- established companies in the market with a major market share
• Tier 2 players
• Emerging players which are growing rapidly
• New Entrants

FutureWise Key Takeaways:
• Growth prospects
• SWOT analysis
• Key trends
• Key data-points affecting market growth

Objectives of the Study:
• To provide with an exhaustive analysis on the global auto injectors market By Therapy, By Type, By End User, By Route Of Administration and by region
• To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
• To evaluate and forecast micro-markets and the overall market 
• To predict the market size, in key regions (along with countries)— North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
• To record evaluate and competitive landscape mapping- product launches, technological advancements, mergers and expansions

Flexible Delivery Model:
• We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
• The customization Mobility Care offered are free of charge with purchase of any license of the report
• You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents

1. Market Introduction
          1.1 Objectives of the Study
          1.2 Market Definition
          1.3 Market Scope
               1.3.1 Years Considered for the Study
               1.3.2 Market Covered
          1.4 Currency
          1.5 Limitations
          1.6 Stakeholders
 
2.  Research Methodology
      2.1 Research Data
         2.1.1 Secondary Data
                 2.1.1.1 Key Data from Secondary Sources
         2.1.2 Primary Data
                 2.1.2.1 Key Data from Primary Sources
      2.2 Market Size Estimation
      2.3 Market Breakdown and Data Triangulation
      2.4 Assumptions for the Study 

3. Executive Summary
        3.1 Market Outlook
        3.2 Segment Outlook
        3.3 Competitive Insights

4. Auto Injectors Market Variables, Trends & Scope
       4.1. Market Lineage Outlook
       4.2. Penetration and Growth Prospect Mapping
       4.3. Industry Value Chain Analysis
       4.4. Cost Analysis Breakdown
       4.5. Technology Overview
       4.6. Regulatory Framework
                 4.6.1. Reimbursement Framework
                 4.6.2. Standards And Compliances

5. Auto Injectors Market Overview
     5.1. Market Dynamics
                  5.1.1. Market Driver Analysis
                            5.1.1.1. Increasing focus of Auto Injectors Companies on Brand Protection
                            5.1.1.2. Untapped Opportunities in Emerging Regions
                  5.1.2. Market Restraint Analysis
                            5.1.2.1. High Cost Associated with Implementation of Predictive Analysis
                  5.1.3. Industry Challenges
                            5.1.3.1. Presence of Ambiguous Regulatory Framework

6. Auto Injectors Market Analysis Tools
         6.1. Industry Analysis - Porter’s
               6.1.1. Supplier Power
               6.1.2. Buyer Power
               6.1.3. Substitution Threat
               6.1.4. Threat from New Entrants
               6.1.5. Competitive Rivalry
         6.2. Pestel Analysis
               6.2.1. Political Landscape
               6.2.2. Environmental Landscape
               6.2.3. Social Landscape
               6.2.4. Technology Landscape
               6.2.5. Legal Landscape
         6.3. Major Deals And Strategic Alliances Analysis
                6.3.1. Joint Ventures
                6.3.2. Mergers and Acquisitions
                6.3.3. Licensing and Partnership
                6.3.4. Technology Collaborations
                6.3.5. Strategic Divestments
         6.4. Market Entry Strategies
         6.5. Case Studies

7. Auto Injectors Market, By Therapy Historical Analysis and Forecast 2022-2028 (USD Million)
         7.1. Rheumatoid Arthritis
         7.2. Multiple Sclerosis
         7.3. Diabetes
         7.4. Anaphylaxis
         7.5. Other Therapies

8. Auto Injectors Market, By Type Historical Analysis and Forecast 2022-2028 (USD Million)
         8.1. Disposable Auto Injectors
         8.2. Reusable Auto Injectors
                8.2.1. Prefilled Auto Injectors
                8.2.2. Empty Auto Injectors

9. Auto Injectors Market, By End User Historical Analysis and Forecast 2022-2028 (USD Million)
         9.1. Home Care Settings           
         9.2. Hospitals & Clinics
         9.3. Ambulatory Care Settings

10. Auto Injectors Market, By Route of Administration Historical Analysis and Forecast 2022-2028 (USD Million)
         10.1. Subcutaneous    
         10.2. Intramuscular

11. North America Auto Injectors Market Analysis 2016–2020 and Forecast 2022–2028 (USD Million)
   11.1. Introduction
   11.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
        11.2.1. U.S.A
        11.2.2. Canada
        11.2.3. Mexico
   11.3. Market Size (USD Million) Forecast for North America 2022-2028

12. Latin America Auto Injectors Market Analysis 2016–2020 and Forecast 2022–2028 (USD Million)
    12.1. Introduction
    12.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
          12.2.1. Brazil
          12.2.2. Venezuela
          12.2.3. Argentina
          12.2.4. Rest of Latin America
    12.3. Market Size (USD Million) Forecast for Latin America 2022-2028

13. Europe Auto Injectors Market Analysis 2016–2020 and Forecast 2022–2028 (USD Million)
    13.1. Introduction
    13.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
          13.2.1. Germany
          13.2.2. U.K         
          13.2.3. France
          13.2.4. Italy
          13.2.5. Spain
          13.2.6. Russia
          13.2.7. Poland
          13.2.8. Rest of Europe
    13.3. Market Size (USD Million) Forecast for Europe 2022-2028

14. Asia Pacific Auto Injectors Market Analysis 2016–2020 and Forecast 2022–2028 (USD Million)
    14.1. Introduction
    14.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
          14.2.1. Japan
          14.2.2. China
          14.2.3. India
          14.2.4. Australia and New Zealand
          14.2.5. ASEAN
          14.2.6. Rest of Asia Pacific
    14.3. Market Size (USD Million) Forecast for Asia Pacific 2022-2028  

15. Middle East and Africa Market Analysis 2016–2020 and Forecast 2022–2028 (USD Million)
    15.1. Introduction
    15.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
          15.2.1. GCC
          15.2.2. Israel
          15.2.3. South Africa
          15.2.4. Rest of MEA
    15.3. Market Size (USD Million) Forecast for MEA 2022-2028

16. Market Share Analysis and Competitive Landscape   
    16.1. Global Landscape - Key Players, Revenue and Presence
    16.2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
    16.3. Global Emerging Companies
    16.4.  North America - Market Share Analysis and Key Regional Players
    16.5.  Europe - Market Share Analysis and Key Regional Players
    16.6.  Asia Pacific - Market Share Analysis and Key Regional Players
    16.7.  Global Key Player - Growth Matrix

17. Company Profiles (Competition Dashboard, Competitors Deep Dive, Product Connected Devices and Disease Indication Portfolio, Financial Layouts)
         17.1. Abbvie
                17.1.1. Company Overview
                17.1.2. Product Portfolio
                17.1.3. SWOT Analysis
                17.1.4. Financial Overview
                17.1.5. Strategic Overview
         17.2. Mylan
                17.2.1. Company Overview
                17.2.2. Product Portfolio
                17.2.3. SWOT Analysis
                17.2.4. Financial Overview
                17.2.5. Strategic Overview
         17.3. ELI Lilly
                17.3.1. Company Overview
                17.3.2. Product Portfolio
                17.3.3. SWOT Analysis
                17.3.4. Financial Overview
                17.3.5. Strategic Overview
           17.4. Ypsomed
                17.4.1. Company Overview
                17.4.2. Product Portfolio
                17.4.3. SWOT Analysis
                17.4.4. Financial Overview
                17.4.5. Strategic Overview
          17.5 Amgen
                17.5.1. Company Overview
                17.5.2. Product Portfolio
                17.5.3. SWOT Analysis
                17.5.4. Financial Overview
                17.5.5. Strategic Overview
          17.6 Becton Dickinson and Co.
                17.6.1. Company Overview
                17.6.2. Product Portfolio
                17.6.3. SWOT Analysis
                17.6.4. Financial Overview
                17.6.5. Strategic Overview
           17.7. Owen Mumford
                17.7.1. Company Overview
                17.7.2. Product Portfolio
                17.7.3. SWOT Analysis
                17.7.4. Financial Overview
                17.7.5. Strategic Overview
           17.8. Consort Medical
                17.8.1. Company Overview
                17.8.2. Product Portfolio
                17.8.3. SWOT Analysis
                17.8.4. Financial Overview
                17.8.5. Strategic Overview
           17.9. Haselmeir
                17.9.1. Company Overview
                17.9.2. Product Portfolio
                17.9.3. SWOT Analysis
                17.9.4. Financial Overview
                17.9.5. Strategic Overview
         17.10. Shl Group
                17.10.1. Company Overview
                17.10.2. Product Portfolio
                17.10.3. SWOT Analysis
                17.10.4. Financial Overview
                17.10.5. Strategic Overview
         17.11. Johnson & Johnson
                17.11.1. Company Overview
                17.11.2. Product Portfolio
                17.11.3. SWOT Analysis
                17.11.4. Financial Overview
                17.11.5. Strategic Overview
         17.12. Teva
                17.12.1. Company Overview
                17.12.2. Product Portfolio
                17.12.3. SWOT Analysis
                17.12.4. Financial Overview
                17.12.5. Strategic Overview
         17.13. Antares Pharma
                17.13.1. Company Overview
                17.13.2. Product Portfolio
                17.13.3. SWOT Analysis
                17.13.4. Financial Overview
                17.13.5. Strategic Overview
         17.14. Sanofi
                17.14.1. Company Overview
                17.14.2. Product Portfolio
                17.14.3. SWOT Analysis
                17.14.4. Financial Overview
                17.14.5. Strategic Overview
         17.15. Pfizer, Inc.
                17.15.1. Company Overview
                17.15.2. Product Portfolio
                17.15.3. SWOT Analysis
                17.15.4. Financial Overview
                17.15.5. Strategic Overview

18. Pre and Post COVID-19 Impact
    18.1. Positive influence on the healthcare industry
    18.2. The financial disruption of the manufacturing sector
    18.3. Impact of COVID-19 on emerging companies
    18.4. Significant mandates in the healthcare regulations initiated by administrations
    18.5. The overall economic slowdown of the developing and developed nations

19. FutureWise SME Key Takeaway Points for Client

Tables

Figures